Cyano Biotech Is Now Simris Biologics

Cyano Biotech, now Simris Biologics after its acquisition by the Simris Group in August 2022, is worldwide leading in applied R&D on cyanobacteria and microalgae. The company’s business is based on (1) natural product libraries for drug discovery (2) off-the-shelf cyanotoxin standards for analytic & bio-reagents for research (3) contract research towards the development of natural products for the pharmaceutical, (agro)chemical, and cosmetics industries. Besides its own drug discovery program, Cyano Biotech collaborates with international pharmaceutical, agrochemical and life science companies. • Key products: - Different types of natural product libraries (biomasses, crude extracts, pre-fractionated extracts, pure compounds) in MTP format for HTS - Patented Microcystin (MC)-based ADC payloads for targeted cancer therapies, with multi-modal mode of action & favorable safety profile + proven in-vitro- & in-vivo-efficacy (comprehensive pre-clinical data available) - Analytical reference standards of diverse cyanotoxins (e.g. for quantification of toxins in water bodies) and bio-reagents of bioactive natural products from cyanobacteria (e.g. for physiological & biochemical research) - Contract R&D services: e.g. Microcystin libraries with variable conjugation chemistries for coupling to linker and mAb; further ADC (or AAC) payloads based on potent cytotoxic (or anti-infective) non-ribososmal peptides from cyanobacteria (e.g. Nodularins, Cryptophycins, Largazoles, Apratoxins etc.); strain development of industrial producer strains by genetic engineering + process development & scale-up for GMP manufacturing • Core competencies: - Unique strain & compound collection, patent-protected assets and methods, from natural-product-based drug discovery and development to industrial production • Modern lab and production infrastructure: - State-of-the-art equipment for natural-product-based drug discovery & development, cultivation, downstream processing, analytics